CCN2 and carcinoma: ZEB1 can switch from a repressor into a transcriptional activator in conjunction with the Hippo pathway effector Yes-associated protein (YAP), promoting the transcription of a subset of YAP target genes, such as AXL receptor tyrosine kinase (AXL), cyclin-dependent kinase inhibitor 2C (CDKN2C), connective tissue growth factor (CTGF), cysteine-rich protein 61 (Cyr61) and DAB adaptor protein 2 (DAB2), which drive carcinoma progression and metastasis [13].